No Data
No Data
No Data
No Data
No Data
Immix Biopharma on Track to Dose First Patients With AL Amyloidosis Therapy by Mid-Year
Immix Biopharma (IMMX) Thursday said it is on track to dose first patients with relapsed or refractory AL Amyloidosis with its CAR-T NXC-201 therapy candidate by mid-2024 after scheduling initiation v
MT Newswires16:12 ET
Immix Biopharma on Track to Dose NXC-201 Patients in United States
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No
GlobeNewswireApr 18 09:32 ET
Express News | Immix Biopharma Announces Late-Breaking Nxc-201 Clinical Data Abstract Accepted for Oral Presentation at the 27TH Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)
Moomoo 24/7Apr 15 09:36 ET
Express News | Immix Biopharma Announces Comprehensive Cancer Center As Lead Site For NXC-201 AL Amyloidosis Clinical Trial
Moomoo 24/7Mar 20 09:52 ET
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (NASDAQ:IMMX) ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL
GlobeNewswireMar 20 09:46 ET
Immix Biopharma Announces 12-Month Progress Update Including Shareholder Letter
Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder le
BenzingaFeb 21 09:39 ET
Seraphicall : Offering 2.71. Nice
TrytosaveabitOP Seraphicall: And it’s a private placement! GL
No Data
No Data